Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of thymosin beta-4 in patients with epidermolysis bullosa

Trial Profile

A phase III trial of thymosin beta-4 in patients with epidermolysis bullosa

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2018

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Sponsors G-treeBNT; ReGenTree
  • Most Recent Events

    • 29 Oct 2018 According to a RegeneRx Biopharmaceuticals media release, this trial is expected to be initiated in 2019.
    • 14 Feb 2018 Planned initiation date changed from 1 Jul 2017 to 1 Jan 2018, according to a RegeneRx Biopharmaceuticals media release.
    • 14 Feb 2018 According to a RegeneRx Biopharmaceuticals media release, the trial is expected to initiate in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top